Placental transfer of the HIV protease inhibitor darunavir was investigated in 5 term human cotyledons perfused with darunavir (1,000 ng/ml) in the maternal to fetal direction. The mean (؎ the standard deviation [SD]) fetal transfer rate (FTR) (fetal/maternal concentration at steady state from 30 to 90 min) was 15.0% ؎ 2.1%, and the mean (؎SD) clearance index (darunavir FTR/ antipyrine FTR) was 40.3% ؎ 5.8%. This shows that darunavir crosses the placenta at a relatively low rate, resulting in fetal exposure.
T
he use of antiretroviral drugs has allowed for a spectacular reduction in mother-to-child transmission (MTCT) of HIV in the industrialized countries, with a current rate of Յ0.5% in France (1, 2) . Darunavir is an HIV protease inhibitor (PI) that is increasingly used in combination with other drugs to treat HIV infection. It is now considered a first-line option in pregnant women (3, 4) , although few data are available to date on its effects during pregnancy. It is classified by the FDA in pregnancy category C (4), meaning that animal studies have failed to demonstrate a risk to the fetus, but there have been no adequate and well-controlled studies in pregnant women. Most of the adverse events described are related to nucleoside reverse transcriptase inhibitors, particularly mitochondrial disease (6) and hematologic or cardiac function toxicities (7) , whereas few antiretroviral drugs have shown any relation to the risk of malformations (8) . The HIV protease inhibitors are largely well tolerated in utero (9) , although there are reports of elevated neonatal bilirubin levels following atazanavir exposure (10) and transient adrenal dysfunction following perinatal lopinavir-ritonavir treatment (11) . Determining fetal exposure to a specific drug is important in estimating its potential for preexposure prophylaxis (12) , as well as its risk for toxicities in the fetus. Since data from animal studies are difficult to extrapolate to humans due to the differences in placental physiology, human studies are required. There are some data on cord blood concentrations of darunavir at delivery, but these data reflect only a single time point, and larger series are required for population pharmacokinetic modeling (13, 14) . The ex vivo human cotyledon is an accepted model in which to study and interpret placental transfer (15) .
The purpose of this study was to investigate the placental transfer of darunavir in the ex vivo human perfused cotyledon.
Placentas were collected after uneventful pregnancies and term deliveries (Ն37 weeks gestational age) in a single center (a university hospital maternity department in Colombes, France) and were rapidly perfused on site. Written informed consent was obtained from each woman who donated a placenta, according to French bioethics guidelines (article L1211-2 of the Public Health Code).
The darunavir base was provided by the manufacturer (Janssen, Issy-les-Moulineaux, France) as antipyrine-phosphate-buffered saline (PBS). Bradford reagent was purchased from SigmaAldrich (Saint Quentin Fallavier, France), other reagents from Invitrogen (Cergy Pontoise, France), and albumin from Baxter Laboratories (Deerfield, IL).
Placentas were perfused according to a method adapted from Schneider et al. (16) as previously described (17, 18) . All perfusions were started within 20 min after delivery. An intact isolated cotyledon was selected, and a chorionic plate artery and its associated vein were cannulated. A lack of difference in pressure between the fetal artery and the vein was required to confirm that the cotyledon was viable. The maternal side was then examined for whitening of the perfused area, and the selected cotyledon was placed in the perfusion chamber with the maternal side up. The intervillous space on the maternal side was perfused by two needles piercing the basal plate. The two circuits were pumped separately by peristaltic pumps (Minipuls 3; Gilson Medical Electronics, Villiers le Bel, France). The fetal and maternal flow rates were 6 and 12 ml/min, respectively. The system reached steady state after 15 to 30 min. The pH values of the maternal and fetal solutions, prepared with Earle medium plus human albumin at 2 g/liter, were adjusted to 7.4 Ϯ 0.1 and 7.2 Ϯ 0.1, respectively, and the temperature was maintained at 37°C. Antipyrine, an inert molecule which freely diffuses through the placenta, was added at 20 mg/liter as a marker to validate each cotyledon's viability throughout the experiment. Darunavir concentrations in the maternal perfusate were targeted to be in the range of clinical trough plasma levels (C min ). Darunavir and antipyrine were perfused into the maternal reservoir. Samples were collected every 15 min to determine their concentrations in the fetal and maternal compartments. They were then stored at Ϫ20°C until analysis.
Darunavir concentrations in the maternal and fetal samples were determined using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry, as previously described (19) . The lower limit of quantification for darunavir was 5 ng/ml. Antipyrine concentrations were determined by high-performance liquid chromatography with UV detection at 290 nm after liquid-liquid extraction. The analytic column for antipyrine separation consisted of an octadecylsilyl NovaPak (3.9 mm by 150 mm). The mobile phase comprised 0.05 M phosphate buffer (pH 3)-methanol-tetrahydrofuran (75:25:0.9 [vol/vol/vol]). Standard curves for antipyrine concentrations ranged from 0.5 to 20 mg/liter. The lower limit of quantification for antipyrine was 0.01 mg/liter.
Maternal-to-fetal transfer parameters were calculated at steady state according to the formulas of Challier et al. (20) . The fetal transfer rate (FTR) is the ratio of fetal to maternal concentrations, and the clearance index (CLI) is the ratio of the FTR of darunavir over the FTR of antipyrine. An antipyrine FTR of Ͼ20% was required to validate each experiment.
Eight full-term placentas were donated by mothers who were seronegative for HIV and hepatitis B and C and who had taken no medication, except for vitamin supplements and perimedullar analgesia. Of eight placentas that were perfused, five procedures were validated, with a mean (Ϯ standard deviation [SD]) antipyrine FTR of 35.8% Ϯ 6.6%. The results of the five experiments at steady state are summarized in Table 1 .
The mean (ϮSD) concentration in the maternal compartment was 903 Ϯ 308 ng/ml, about 16 times the 50% effective concentration (EC 50 ) against wild-type HIV (55 ng/ml, corrected for plasma protein binding) (21) . The mean concentration in the fetal compartment was 132 Ϯ 32 ng/ml, which is still well above this EC 50 .
The mean (ϮSD) FTR of darunavir was 15.2% Ϯ 3.2%, and the mean (ϮSD) clearance index (CLI) was 35.6% Ϯ 5.0%.
There was a fairly good correlation between the maternal and fetal concentrations (coefficient of correlation, 0.81).
This study indicates that about one-sixth of maternal darunavir is transferred across the human placenta. The mean trough level in the fetal compartment was 140 ng/ml, near the suggested minimum effective concentration for darunavir, reported to be 150 ng/ml (22) . Clinical data on darunavir use in pregnant women are still limited to small case series, but the available pharmacological data are compatible with our findings. In matched maternal and cord plasma samples at delivery, the median cord/maternal plasma ratios of the darunavir concentrations were, respectively, 0.18 (range, 0.10 to 0.24) (23), 0.11 (24) , 0.24 (25) , and 0.15 (26) .
The cord/maternal ratios for darunavir were quite similar to those reported for other currently used PIs. For atazanavir, the ratios were 0.13 (27) to 0.21 (10) , and for lopinavir, the ratio was 0.20 (28) . Similar ratios were also observed for nelfinavir and amprenavir (29) , whereas cord blood concentrations were nearly undetectable for ritonavir, indinavir, and saquinavir (29, 30) .
As for darunavir in the present study, the ex vivo placental perfusion results were consistent with in vivo data for other protease inhibitors. For lopinavir combined with ritonavir, we previously reported (31) a mean (ϮSD) FTR of 23.6% Ϯ 6.9% and a mean (ϮSD) clearance index of 73% Ϯ 16% at an albumin concentration of 2 g/liter. The fetal transfer rates decreased at higher albumin concentrations. For nelfinavir, the mean (ϮSD) FTR was 14% Ϯ 3.4% and the mean (ϮSD) clearance index was 39% Ϯ 10% (15) . For saquinavir, there was nearly no placental transfer (17) . Interestingly, among the protease inhibitors, those which are more lipophilic than darunavir and highly protein bound have lower placental transfer rates (17, 31) . The protein binding rate for darunavir is 95%, which is considerably less than that for lopinavir or ritonavir and somewhat more than that for atazanavir (26) . Darunavir is a substrate of efflux transporters expressed in the placenta, as are the HIV protease inhibitors, in general (32) , and some other antiretroviral drugs (18) , resulting in decreased fetal exposure (33) .
The results obtained with the ex vivo placental perfusion model have already been validated for various antiretroviral agents (15) . The main limitation is that the model evaluates placental transfer at term and not during the entire pregnancy. The same is true for clinical cord blood data at delivery. Although the experiments do not entirely reproduce in vivo conditions, the procedure is carefully monitored and standardized to approach normal physiology, and the FTR of antipyrine is monitored in order to control the integrity of the placental barrier.
The maternal plasma concentration decreases for darunavir, as for other protease inhibitors, in the third trimester of pregnancy (23, 26) , although Zorrilla et al. (26) observed that the plasma concentrations of unbound darunavir do not decrease. Twicedaily dosing is now recommended during pregnancy (3) . The darunavir concentrations that we perfused in the maternal compartment were below the mean trough plasma concentration reported in late pregnancy, which was 1,407 ng/ml for once-daily darunavir (800 mg) plus ritonavir (100 mg) (24) . In clinical studies of cord/maternal concentrations at delivery (23), maternal darunavir concentrations were widely dispersed, reflecting the variable timing between the last dose taken and the delivery. We chose not to add ritonavir to darunavir in the experiments because it was not required to increase the bioavailability, since the drug is added directly into the maternal perfusate and because there is little placental transfer of ritonavir and no accumulation in the placenta (34) .
In conclusion, the placental transfer of darunavir appears to be limited, on the same order as that of most of the other protease inhibitors, but sufficient to expose the fetus to drug concentrations near the therapeutic range. This may have some effect as preexposure prophylaxis (PrEP), but it also carries a potential for adverse effects. Furthermore, protease inhibitors may accumulate in the fetus during gestation, as has been suggested from studies using neonatal hair samples to determine lopinavir and ritonavir concentrations (35) . Clinical studies are required to determine whether darunavir has a more favorable safety and efficacy profile than those of other protease inhibitors for use in pregnant women.
